Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 74
Filter
1.
Aliment Pharmacol Ther ; 47(4): 494-503, 2018 02.
Article in English | MEDLINE | ID: mdl-29243850

ABSTRACT

BACKGROUND: Serum pepsinogen 1 (SPG1) and anti-Helicobacter pylori serology have been used for gastric risk stratification in Asia. AIM: To assess utility of these markers in a Western population. METHODS: SPG1 measurements were available for 21 895 Finnish male smokers in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. We used Cox proportional hazards models adjusted for potential confounders to estimate gastric cancer hazard ratios (HR) and 95% confidence intervals (95% CI) for low SPG1 (<25 µg/L). In a subset (n = 3555) with anti-H. pylori serology, these markers jointly defined the following: Group A (H. pylori[-], SPG1[normal]; reference group), Group B (H. pylori[+], SPG1[normal]), Group C (H. pylori[+], SPG1[low]) and Group D (H. pylori[-], SPG1[low]). Odds ratios (ORs) and 95% CI were calculated using multivariate logistic regression. RESULTS: There were 329 gastric cancers diagnosed an average of 13.9 years after baseline. Pre-diagnostic low SPG1 was significantly associated with increased gastric cancer risk (HR 2.68, 95% CI 1.99-3.61). Among subjects with both SPG1 and H. pylori serology, groups B, C and D had increased gastric cancer ORs (95% CI) of 1.79 (1.21-2.64), 3.85 (2.36-6.28) and 6.35 (2.20-18.34), respectively. CagA seropositives had significantly higher ORs than CagA seronegatives within group B (Pheterogeneity  = 0.01). For groups B and C, repeat SPG1 level at 3 years did not further stratify gastric cancer risk. CONCLUSIONS: Low SPG1 was associated with increased gastric cancer risk in our large Finnish cohort. A single measurement of SPG1 along with H. pylori whole cell and CagA serology provides potentially useful prediction of gastric cancer risk.


Subject(s)
Antibodies, Bacterial/blood , Helicobacter Infections/complications , Helicobacter Infections/diagnosis , Helicobacter pylori/immunology , Immunoglobulin G/blood , Pepsinogen A/blood , Stomach Neoplasms/diagnosis , Aged , Biomarkers/blood , Cohort Studies , Finland/epidemiology , Helicobacter Infections/blood , Helicobacter Infections/epidemiology , Humans , Male , Middle Aged , Prognosis , Randomized Controlled Trials as Topic , Registries , Risk Factors , Sex Factors , Stomach Neoplasms/blood , Stomach Neoplasms/epidemiology , Stomach Neoplasms/microbiology
2.
Genes Immun ; 16(8): 567-70, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26312625

ABSTRACT

A genome-wide association study among Europeans related polymorphisms of the Toll-like receptor (TLR) locus at 4p14 and the Fcγ receptor 2a locus at 1q23.3 to Helicobacter pylori serologic status. We replicated associations of 4p14 but not 1q23.3 with anti-Helicobacter pylori antibodies in 1402 Finnish males. Importantly, our analysis clarified that the phenotype affected by 4p14 is quantitative level of these antibodies rather than association with seropositivity per se. In addition, we annotated variants at 4p14 as expression quantitative trait loci (eQTL) associated with TLR6/10 and FAM114A1. Our findings suggest that 4p14 polymorphisms are linked to host immune response to H. pylori infection but not to its acquisition.


Subject(s)
Helicobacter Infections/genetics , Helicobacter Infections/immunology , Helicobacter pylori/physiology , Quantitative Trait Loci , Toll-Like Receptor 10/genetics , Toll-Like Receptor 6/genetics , Antibodies, Bacterial/genetics , Antibodies, Bacterial/immunology , Finland , Genome-Wide Association Study , Humans , Male , Polymorphism, Genetic , Toll-Like Receptor 10/immunology , Toll-Like Receptor 6/immunology
4.
Br J Cancer ; 105(1): 38-43, 2011 Jun 28.
Article in English | MEDLINE | ID: mdl-21654677

ABSTRACT

BACKGROUND: Meta-analyses of the published literature indicate that about 9% of gastric cancers contain Epstein-Barr virus (EBV), with consistent and significant differences by sex and anatomic subsite. This study aimed to identify additional determinants of EBV positivity and their joint effects. METHODS: From 15 international populations with consistent laboratory testing for EBV, we pooled individual-level data for 5081 gastric cancer cases including information on age, sex, subsite, histologic type, diagnostic stage, geographic region, and period of diagnosis. First, we combined population-specific EBV prevalence estimates using random effects meta-analysis. We then aggregated individual-level data to estimate odds ratios of EBV positivity in relation to all variables, accounting for within-population clustering. RESULTS: In unadjusted analyses, EBV positivity was significantly higher in males, young subjects, non-antral subsites, diffuse-type histology, and in studies from the Americas. Multivariable analyses confirmed significant associations with histology and region. Sex interacted with age (P=0.003) and subsite (P=0.002) such that male predominance decreased with age for both subsites. The positivity of EBV was not significantly associated with either stage or time period. CONCLUSION: Aggregating individual-level data provides additional information over meta-analyses. Distinguishing histologic and geographic features as well as interactions among age, sex, and subsite further support classification of EBV-associated gastric cancer as a distinct aetiologic entity.


Subject(s)
Adenocarcinoma/virology , Carcinoma, Signet Ring Cell/virology , Epstein-Barr Virus Infections/virology , Herpesvirus 4, Human/genetics , Stomach Neoplasms/virology , Adenocarcinoma/genetics , Aged , Carcinoma, Signet Ring Cell/genetics , Epstein-Barr Virus Infections/genetics , Female , Humans , International Agencies , Male , Meta-Analysis as Topic , Middle Aged , Prognosis , Stomach Neoplasms/genetics
5.
Carcinogenesis ; 28(1): 118-23, 2007 Jan.
Article in English | MEDLINE | ID: mdl-16885196

ABSTRACT

Helicobacter pylori infection, the dominant risk factor for gastric cancers, has been shown to elicit T helper type 1 (Th1) polarized immunological responses. We conducted a population-based study of 305 gastric cancer cases and 427 age- and gender-matched controls in Warsaw, Poland, to evaluate the association with several variants in genes responsible for Th1-cell-mediated response. Genotyping was performed on genomic DNA by TaqMan(TM) assays to determine TNFA (-308 G>A, -417 G>A, -555 G>A, -1036 C>T, -1042 C>A, -1210 T>C), IL1A (-889 C>T), IFNGR2 (Ex7-128 T>C, Ex2-34 C>G and Ex2-16 A>G) and IL12A (IVS2-798 T>A, IVS2-701 C>A and Ex7+277 G>A) polymorphisms. We used unconditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for sex, age, education and smoking status. Out of six single nucleotide polymorphisms (SNPs) tested in TNFA, gastric cancer risk was significantly associated with the TNFA (-308 G>A) polymorphism, with ORs of 1.4 (95% CI: 1.0-2.0) for the G/A and 2.5 (95% CI: 1.3-4.9) for the A/A genotype carriers, when compared with the more frequent genotype (G/G) (P-trend < 0.001). Among the three tested SNPs in the IFNGR2 gene, only the Ex7-128C>T polymorphism was associated with increased risk, with ORs of 1.5 (95% CI: 1.0-2.3) for T/C and 1.7 (95% CI: 1.1-2.7) for C/C carriers when compared with T/T carriers (P-trend = 0.01). Subjects carrying both IFNGR2 Ex7-128 C/C and TNFA -308 A/A genotypes had the highest risk (OR = 5.5, 95% CI: 1.5-19.4), although the interaction was not statistically significant. IL1A (-889 C>T) and the three examined IL12A variants were unrelated to gastric cancer risk. Our findings suggest that two Th1-related polymorphisms (TNFA -308 A>G and IFNGR2 Ex7-128 C>T) may increase the risk of gastric cancer.


Subject(s)
Interleukin-12 Subunit p35/genetics , Polymorphism, Single Nucleotide/genetics , Receptors, Interferon/genetics , Stomach Neoplasms/genetics , Th1 Cells/metabolism , Tumor Necrosis Factor-alpha/genetics , Adult , Aged , Case-Control Studies , Female , Genetic Predisposition to Disease , Genotype , Humans , Male , Middle Aged , Odds Ratio , Poland , Risk Factors , Smoking , Stomach Neoplasms/metabolism
6.
Biomarkers ; 11(5): 472-9, 2006.
Article in English | MEDLINE | ID: mdl-16966163

ABSTRACT

Buccal cell samples are increasingly used in epidemiological studies as a source of genomic DNA. The accurate and precise quantitation of human DNA is critical for the optimal use of these samples. However, it is complicated by the presence of bacterial DNA and wide inter-individual variation in DNA concentration from buccal cell collections. The paper evaluated the use of ultraviolet light (UV) spectroscopy, Höechst (H33258) and PicoGreen as measures of total DNA, and real-time quantitative polymerase chain reaction (PCR) as a measure of human amplifiable DNA in buccal samples. Using serially diluted white blood cell DNA samples (at a concentration range of 300 to 0.5 ng microl-1), UV spectroscopy showed the largest bias, followed by Höechst, especially for low concentrations. PicoGreen and real-time PCR provided the most accurate and precise estimates across the range of concentrations evaluated, although an increase in bias with decreasing concentrations was observed. The ratio of real-time PCR to PicoGreen provided a reasonable estimate of the percentage of human DNA in samples containing known mixtures of human and bacterial DNA. Quantification of buccal DNA from samples collected in a breast cancer case-control study by PicoGreen and real-time PCR indicated that cytobrush and mouthwash DNA samples contain similar percentages of human amplifiable DNA. Real-time PCR is recommended for the quantification of buccal cell DNA in epidemiological studies since it provides precise estimates of human amplifiable DNA across the wide range of DNA concentrations commonly observed in buccal cell DNA samples.


Subject(s)
Cheek , DNA/analysis , Epidemiologic Studies , Mouth Mucosa/chemistry , Humans , Polymerase Chain Reaction , Reproducibility of Results , Spectrophotometry, Ultraviolet
7.
Br J Cancer ; 95(5): 642-8, 2006 Sep 04.
Article in English | MEDLINE | ID: mdl-16868538

ABSTRACT

By linking HIV/AIDS and cancer surveillance data in 12 US regions, breast and reproductive cancer risks with AIDS were compared to those in the general population. Trends in standardized incidence ratios (SIRs) were assessed by CD4 count, AIDS-relative time, and calendar time. Standardized incidence ratios were indirectly adjusted for cancer risk factors using data from AIDS cohort participants and the general population. With AIDS, 313 women developed breast cancer (SIR 0.69, 95% confidence interval (CI) 0.62-0.77), 42 developed ovary cancer (SIR 1.05, 95% CI, 0.75-1.42), and 31 developed uterine corpus cancer (SIR 0.57, 95% CI, 0.39-0.81). Uterine cancer risk was reduced significantly after age 50 (SIR 0.33). Breast cancer risk was reduced significantly both before (SIR 0.71) and after (SIR 0.66) age 50, and was lower for local or regional (SIR 0.54) than distant (SIR 0.89) disease. Breast cancer risk varied little by CD4 count (Ptrend=0.47) or AIDS-relative time (Ptrend=0.14) or after adjustment for established cancer risk factors. However, it increased significantly between 1980 and 2002 (Ptrend=0.003), approaching the risk of the general population. We conclude that the cancer deficit reflected direct or indirect effects of HIV/AIDS and that anti-HIV therapy reduced these effects.


Subject(s)
Acquired Immunodeficiency Syndrome/complications , Breast Neoplasms/epidemiology , Ovarian Neoplasms/epidemiology , Uterine Neoplasms/epidemiology , Age Factors , Female , Humans , Incidence , Menopause , Middle Aged , Poisson Distribution , Racial Groups , Registries , Risk , United States/epidemiology
8.
Br J Cancer ; 94(4): 548-51, 2006 Feb 27.
Article in English | MEDLINE | ID: mdl-16449994

ABSTRACT

Mouse mammary tumour virus (MMTV) causes breast cancer in mice, and MMTV-specific antibodies develop to high titers among mice infected as adults. Whether MMTV or a related virus infects humans is uncertain, because MMTV DNA sequences have been detected inconsistently and because serologic methods have varied widely. The current study used immunoblot and immunoprecipitation with four strains of MMTV (RIII, FM, C3H, and LA) to detect specific antibodies in 92 sera from US women with breast cancer and in masked dilutions of monoclonal hybridoma and hyperimmunised goat positive-control reagents. In these positive controls, MMTV antibodies of the expected molecular weights were detected at high titer (1 : 100 in the monoclonal reagent, 1 : 10000 in the hyperimmunised goat serum). Nearly 30% of the sera from women with breast cancer had at least one faint band on an immunoblot, but none of these matched the molecular weight of bands revealed by probing the same blot strips with the goat serum. The goat serum readily immunoprecipitated MMTV antigens from all four strains of MMTV, but MMTV antigens were not immunoprecipitated by any of the six breast cancer sera that had four or more nonspecific immunoblot bands. Thus, among women with breast cancer, we found no MMTV-specific antibodies. The upper 95% confidence limit implies that MMTV seroprevalence among breast cancer patients does not exceed 3%.


Subject(s)
Antibodies, Viral/analysis , Breast Neoplasms/virology , Mammary Tumor Virus, Mouse/immunology , Mammary Tumor Virus, Mouse/pathogenicity , Antibody Formation , Breast Neoplasms/immunology , Case-Control Studies , Female , Humans , Immunoblotting , Immunoprecipitation , Seroepidemiologic Studies
10.
Cancer Causes Control ; 12(4): 335-41, 2001 May.
Article in English | MEDLINE | ID: mdl-11456229

ABSTRACT

OBJECTIVE: Human papilloma virus (HPV) is frequently detectable in cancers of the cervix, vagina, and vulva, but its role in endometrial and ovarian cancers is less certain. This analysis aimed to examine the association of presence of HPV type 16 (HPV-16) antibodies with subsequent risk of cervical, endometrial, and ovarian cancers. METHODS: In a prospective study enrolling over 15,000 pregnant women, pre-cancer sera from women who developed cervical (n = 83), endometrial (n = 34), and ovarian (n = 35) cancers were compared with sera from 172 control women frequency-matched by age group and race. RESULTS: HPV-16 seropositivity (OR = 2.0, 95% CI 1.0-3.4) was associated with cervical cancer, with the association more prominent for cancers occurring within 10 years of serum sampling (OR = 2.3, 95% CI 1.0-5.3) than cancers occurring later (OR = 1.6, 95% CI 0.75-3.6). Overall, the associations between HPV-16 seropositivity and endometrial (OR = 1.6, 95% CI 0.64-3.8) and ovarian cancers (OR = 1.1, 95% CI 0.43-2.8) were not significant, although the odds ratios for those cancers occurring within 20 years after serum sampling were similar to that for cervical cancer (OR = 2.2 for both). CONCLUSIONS: Our results confirm that HPV-16 infection precedes the development of cervical cancer. Predictability of HPV-16 seropositivity for risk of other female cancers warrants further investigation.


Subject(s)
Antibodies, Viral/blood , Genital Neoplasms, Female/epidemiology , Genital Neoplasms, Female/virology , Papillomaviridae/isolation & purification , Papillomavirus Infections/epidemiology , Tumor Virus Infections/epidemiology , Adult , California/epidemiology , Chi-Square Distribution , DNA, Viral/isolation & purification , Endometrial Neoplasms/epidemiology , Endometrial Neoplasms/virology , Female , Follow-Up Studies , Genital Neoplasms, Female/diagnosis , Humans , Middle Aged , Odds Ratio , Ovarian Neoplasms/epidemiology , Ovarian Neoplasms/virology , Papillomaviridae/genetics , Papillomaviridae/immunology , Papillomavirus Infections/complications , Papillomavirus Infections/immunology , Pregnancy , Prevalence , Prospective Studies , Risk , Tumor Virus Infections/complications , Tumor Virus Infections/immunology , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/virology
11.
Eur J Cancer ; 37(10): 1316-9, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11423263

ABSTRACT

Combination therapy with protease inhibitors and nucleoside analogues dramatically suppresses plasma HIV-1 RNA and delays progression to AIDS, but the impact on HIV-associated malignancy remains to be established. Observational and time-trend data indicate that the incidence of Kaposi's sarcoma (KS) and primary brain lymphoma have decreased, but suggest that current therapies have not had a proportionate effect on systemic non-Hodgkin's lymphomas (NHL). As opportunistic infection and mortality are yielding to advances in antiretroviral therapy, lymphoma may increase in importance as a cause of AIDS-related morbidity and mortality. Further improvements in the long-term consequences of HIV infection will depend on better prevention and treatment of this serious malignant complication.


Subject(s)
Antiretroviral Therapy, Highly Active/methods , Lymphoma, AIDS-Related/complications , Lymphoma, AIDS-Related/drug therapy , Hodgkin Disease/drug therapy , Humans , Risk Factors , Sarcoma, Kaposi/drug therapy
14.
Nature ; 404(6776): 398-402, 2000 Mar 23.
Article in English | MEDLINE | ID: mdl-10746728

ABSTRACT

Helicobacter pylori infection is associated with a variety of clinical outcomes including gastric cancer and duodenal ulcer disease. The reasons for this variation are not clear, but the gastric physiological response is influenced by the severity and anatomical distribution of gastritis induced by H. pylori. Thus, individuals with gastritis predominantly localized to the antrum retain normal (or even high) acid secretion, whereas individuals with extensive corpus gastritis develop hypochlorhydria and gastric atrophy, which are presumptive precursors of gastric cancer. Here we report that interleukin-1 gene cluster polymorphisms suspected of enhancing production of interleukin-1-beta are associated with an increased risk of both hypochlorhydria induced by H. pylori and gastric cancer. Two of these polymorphism are in near-complete linkage disequilibrium and one is a TATA-box polymorphism that markedly affects DNA-protein interactions in vitro. The association with disease may be explained by the biological properties of interleukin-1-beta, which is an important pro-inflammatory cytokine and a powerful inhibitor of gastric acid secretion. Host genetic factors that affect interleukin-1-beta may determine why some individuals infected with H. pylori develop gastric cancer while others do not.


Subject(s)
Helicobacter Infections/complications , Helicobacter pylori , Interleukin-1/genetics , Polymorphism, Genetic , Stomach Neoplasms/genetics , Alleles , Case-Control Studies , Cohort Studies , Gastric Acid/metabolism , Gastritis/complications , Gastritis/immunology , Gastritis/microbiology , Gene Frequency , Genotype , Helicobacter Infections/immunology , Humans , Linkage Disequilibrium , Multigene Family , Risk Factors , Stomach Neoplasms/immunology , Stomach Neoplasms/microbiology
16.
Ann Intern Med ; 132(2): 105-11, 2000 Jan 18.
Article in English | MEDLINE | ID: mdl-10644270

ABSTRACT

BACKGROUND: The sequelae during the first two decades after acute hepatitis C virus (HCV) infection have been well studied, but the outcome thereafter is unknown. OBJECTIVE: To conduct an extended study of the natural history of HCV infection by using archived serum specimens originally collected between 1948 and 1954. DESIGN: Retrospective cohort study. SETTING: A university, a Veterans Affairs medical center, and a medical follow-up agency that had access to the serum specimens and accompanying demographic and medical records. PARTICIPANTS: 8568 military recruits who were evaluated for group A streptococcal infection and acute rheumatic fever between 1948 and 1954. Blood samples were taken from the recruits and, after testing, were stored frozen for almost 45 years. MEASUREMENTS: The presence of antibodies to HCV was determined by enzyme-linked immunoassay, supplementary recombinant immunoblot assay, and polymerase chain reaction for HCV RNA. Morbidity and mortality were also assessed. RESULTS: Of 8568 persons, 17 (0.2%) had positive results on enzyme-linked immunosorbent assay and recombinant immunoblot assay. The rate was 1.8% among the African-American persons and 0.1% among the white persons in the total sample (relative risk, 25.9 [95% CI, 8.4 to 80.0]). During the 45-year follow-up, liver disease occurred in 2 of the 17 HCV-positive persons (11.8%) and 205 of the 8551 HCV-negative persons (2.4%) (ethnicity-adjusted relative risk, 3.56 [CI, 0.94 to 13.52]). Seven of the 17 HCV-positive persons (41 %) and 2226 of the 8551 HCV-negative persons (26%) had died by December 1996 (ethnicity-adjusted relative risk, 1.48 [CI, 0.8 to 2.6]). Of persons who were HCV-positive, 1 (5.9%) died of liver disease 42 years after the original phlebotomy, 5 (29%) died of non-liver-related disease a median of 37 years after the original phlebotomy, and 1 (5.9%) died of unknown causes. One hundred nineteen HCV-negative persons (1.4%) died of liver disease. CONCLUSIONS: The rate of HCV infection from 1948 to 1954 among a sample of military recruits parallels that among present-day military recruits and volunteer blood donors. During 45 years of follow-up, HCV-positive persons had low liver-related morbidity and mortality rates. This suggests that healthy HCV-positive persons may be at less risk for progressive liver disease than is currently thought.


Subject(s)
Hepatitis C/complications , Liver Diseases/etiology , Aged , Cause of Death , Data Interpretation, Statistical , Disease Progression , Follow-Up Studies , Hepacivirus/immunology , Hepatitis C/diagnosis , Hepatitis C/mortality , Hepatitis C Antibodies/blood , Humans , Liver Diseases/epidemiology , Liver Diseases/mortality , Male , Middle Aged , Outcome Assessment, Health Care , Retrospective Studies , Survival Rate
18.
Br J Cancer ; 81(5): 893-7, Nov. 1999.
Article in English | MedCarib | ID: med-718

ABSTRACT

Seroprevalence of HHV-8 has been studied in Malaysia, India, Sri Lanka, Thailand, Trinidad, Jamaica and the USA, in both healthy individuals and those infected with HIV. Seroprevalence was found to be low in these countries. In contrast, the African countries of Ghana, Uganda and Zambia showed high seroprevalences in both healthy and HIV-infected populations. This suggests that human herpes virus-8 (HHV-8) may be either a recently introduced virus or one that has extremely low infectivity. Nasopharyngeal and oral carcinoma patients from Malaysia, Hong Kong and Sri Lanka who have very high EBV titres to show that only 3/82 (3.7 percent) have antibody to HHV-8, demonstrating that there is little, if any, cross-relativity between antibodies to these two gamma viruses. (AU)


Subject(s)
Adult , Aged , Humans , Male , Female , Adolescent , Comparative Study , Child , Middle Aged , Herpesviridae Infections/epidemiology , Herpesvirus 8, Human/immunology , Sarcoma, Kaposi/epidemiology , Africa/epidemiology , Aged, 80 and over , Burkitt Lymphoma/epidemiology , Caribbean Region/epidemiology , Nasopharyngeal Neoplasms/epidemiology , Seroepidemiologic Studies , United States/epidemiology
19.
J Infect Dis ; 180(5): 1466-76, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10515805

ABSTRACT

Molecular polymorphism was found in Kaposi's sarcoma-associated herpesvirus (KSHV) latent nuclear antigen (LNA), mapped to the internal repeat domain of the encoding orf73 gene, and used to develop a novel genotyping technique, KSHV LNA genotyping (KVNAtyping). KVNAtype was stable during latent and lytic viral replication in cell culture and in humans. Diverse KVNAtypes were identified in 43 specimens: 6 KSHV cell lines and 6 Kaposi's sarcoma (KS) and 4 primary effusion lymphoma (PEL) tumor samples from the United States, 15 KS tumor samples from Italy, and 12 KS tumor samples from Zambia. A single KVNAtype was detected in each of 41 specimens, and 2 KVNAtypes were detected in each of 2 KS specimens. Multifocal KS from 3 patients showed the same single KVNAtype at all sites in each patient. These results demonstrate a large repertoire of KSHV genotypes and suggest that the development of most KSs and PELs is associated with a single viral genotype.


Subject(s)
Antigens, Viral/genetics , Herpesvirus 8, Human/genetics , Nuclear Proteins/genetics , Polymorphism, Genetic , Sarcoma, Kaposi/virology , Cell Line , Chromosome Mapping , DNA, Viral/analysis , DNA, Viral/genetics , Genotype , Herpesvirus 8, Human/classification , Herpesvirus 8, Human/immunology , Humans , Polymerase Chain Reaction/methods
20.
J Med Virol ; 59(1): 60-5, Sept. 1999.
Article in English | MedCarib | ID: med-1377

ABSTRACT

Evidence from several sources has suggested that adeno-associated virus (AAV) infection might protect against cervical cancer, in part, by interfering with human papillomavirus (HPV)-induced tumorigenesis. Detection of AAV type 2 (AAV-2) DNA in cervical tissues has been reported. However, there have been few in vivo studies of women with cervical HPV infection or neoplasia, and these have reported inconsistent results. Therefore, we used polymerase chain reaction (PCR) assays targeted to the AAV-2 rep and cap genes to test tissue specimens from women in an epidemiological study of cervical neoplasia in Jamaica. We tested 105 women with low-grade cervical intraepithelial neoplasia (CIN-1), 92 women with CIN-3/carcinoma in situ or invasive cancer (CIN-3/CA), and 94 normal subjects. PCR amplification of human beta-globin DNA was found in almost all cervical specimens, indicating that these materials were adequate for PCR testing. The prevalence of HPV DNA, determined by HPV L1 consensus primer PCR was, as expected, strongly associated with presence and grade of neoplasia. Each of the AAV PCR assays detected as few as 10 copies of the virus genome. However, none of the 291 cervical specimens from Jamaican subjects tested positive for AAV DNA. Negative AAV PCR results were also obtained in tests of cervical samples from 79 university students in the United States. Exposure to AAV was assessed further by serology. Using a whole virus AAV-2 sandwich enzyme-linked immunosorbent assay, we found no relationship between AAV antibodies and presence or grade of neoplasia in either the Jamaican study subjects or women enrolled in a U.S. cervical cancer case (n = 74) - control (n = 77) study. Overall, the data provide no evidence that AAV infection plays a role in cervical tumorigenesis or that AAV commonly infects cervical epithelial cells.(Au)


Subject(s)
Adult , Adolescent , Female , Humans , Middle Aged , Uterine Cervical Neoplasms/virology , Dependovirus/isolation & purification , Parvoviridae Infections/virology , Carcinoma in Situ/virology , Uterine Cervical Dysplasia/virology , Uterine Cervical Neoplasms/epidemiology , Dependovirus/genetics , DNA, Viral/analysis , Globins/genetics , Human Papillomavirus Viruses/genetics , Human Papillomavirus Viruses/isolation & purification , Polymerase Chain Reaction , Tumor Virus Infections/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...